The Pinky Dent Is Real. The Diagnosis Isn't.
Millions of phone users have a visible crease on the side of their pinky. Doctors have been arguing for years about whether it means anything, and a cottage industry has quietly decided it does.
Am I The Idiot — the strongest case against our own take.
The weakest part of this piece is the framing that ties the health-content industry's incentives to the "real condition" side of the argument, as if that settles which camp is right. It doesn't. Incentives explain why a claim spreads, not whether it's true, and this piece risks using "who benefits from saying this" as a stand-in for "is this accurate," which is exactly the kind of shortcut good reporting is supposed to resist.
There's also a real asymmetry in who's being quoted on each side. The skeptics here are a surgeon and a nursing academic, both of whom would mostly see severe, already-diagnosable cases in a clinical setting. The people saying it's real are occupational-health-adjacent voices, including one company that sells a treatment program, but Dr. Evans at Cleveland Clinic, an orthopedic surgeon with no product to sell, also said the nerve-compression risk is real, just narrower than the viral version. A hand surgeon not seeing mild, self-resolving nerve irritation in his operating room doesn't mean it isn't happening; it may just mean it never gets bad enough to reach him. If that's the case, "the surgeons say it's a myth" is a selection-bias problem as much as a evidence problem, and this piece may be leaning on surgeon skepticism harder than the underlying uncertainty justifies.
The single Cureus study is also doing more work in this piece than one regional survey of 500 people should. Its 32.2% self-reported symptom rate is a real number worth citing, but this piece uses it partly to support the idea that awareness lags behind actual experience, and a single-country, single-region, mostly-young, mostly-student sample is a thin base for a claim about a global phenomenon. If a similarly sized study elsewhere came back with very different numbers, the "underappreciated but real" reading this piece leans toward would look considerably weaker.
Finally, this piece's closing swipe, that the pattern here resembles the sticker-price piece's skepticism toward tech company incentives, is a stretch by comparison. Companies that can be shown to control pricing levers are a different kind of claim than a health platform citing a nerve mechanism doctors have separately confirmed is at least plausible. Grouping the two under one house instinct risks making a real, narrower observation about hand health sound more like a conspiracy than the evidence here supports.